AtriCure Reports Strong Q1 2026 Results with 14.3% Revenue Growth and Shift to Profitability

summarizeSummary

AtriCure, Inc. announced strong first-quarter 2026 financial results, featuring 14.3% worldwide revenue growth, a shift to net income, and a 95% increase in adjusted EBITDA, alongside positive full-year guidance.

check_boxKey Events

• Strong Revenue Growth

  Worldwide revenue for Q1 2026 reached $141.2 million, marking a 14.3% increase year-over-year. U.S. revenue growth accelerated to 14.9%, driven by key product lines.

• Shift to Profitability

  The company reported net income of $0.1 million for Q1 2026, a significant improvement from a net loss of $6.7 million in Q1 2025. Basic and diluted net income per share was breakeven at $0.00.

• Substantial EBITDA Growth

  Adjusted EBITDA for Q1 2026 increased by 95% year-over-year to $17.1 million, reflecting enhanced operational efficiency.

• Improved Gross Margin

  Gross margin for the first quarter improved by 246 basis points to 77.4%, primarily due to favorable product and geographic mix.

auto_awesomeAnalysis

AtriCure, Inc. delivered robust first-quarter results, demonstrating accelerated revenue growth and a significant turnaround in profitability. The company's ability to achieve net income after reporting a loss in the prior year, coupled with substantial adjusted EBITDA growth and improved gross margins, indicates strong operational execution. The positive full-year 2026 guidance further reinforces a confident outlook, suggesting continued momentum in its core markets and product lines. This performance provides a solid foundation for the company's growth trajectory.